Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  CardiovascularMedicationType 2 DiabetesIssue 640

Death Risk Drops by 50% for Diabetes Patients Using Statins

Type 2 diabetes patients on statin drugs have lower mortality risk....

Advertisement

In randomized clinical trials, involving 5,152 men and women from 66 to 96 years of age statin medications have been shown to reduce the risk of death in people with type 2 diabetes.

Vilmundur Gudnason, MD, PhD, of the University of Iceland, and colleagues wanted to see if statins had the same beneficial effect in observational studies on older people with type 2 diabetes.

They found that type 2 diabetes patients taking statin drugs had a 50 percent lower risk of dying from heart-related causes and a 53 percent lower risk of dying from all causes, compared to those not taking statins.

Among those without diabetes, statin use was associated with 16 percent lower risk of heart-related death and a 30 percent lower risk of death from all causes.

Diabetes patients who used statins had a similar risk of death as the general population without diabetes. In other words, statin use lowered the risk of death to normal levels, rather than the increased risk generally associated with diabetes.

According to the authors, this observational study adds to a body of evidence showing that statin use may be beneficial for people with type 2 diabetes.

The results urgently call for other population-based studies with comparable information to confirm the effect of statin use on death risk in individuals with type 2 diabetes.

BMJ Open August 2012

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 23 August, 2012 and appeared in  CardiovascularMedicationType 2 DiabetesIssue 640

Past five issues: Issue 796 | Diabetes Clinical Mastery Series Issue 255 | Issue 795 | SGLT-2 Inhibitors Special Edition August 2015 | Diabetes Clinical Mastery Series Issue 254 |

2015 Most Popular Articles:

Coffee Consumption Proves Potential in Reducing Type 2 Diabetes Risk
Posted August 07, 2015
Impaired Glucose Uptake in the Brain May Increase Alzheimer's Disease Risk
Posted August 07, 2015
First Non-Surgical Weight Loss Procedure for Mild-to-Moderate Obesity
Posted August 07, 2015
GLP-1 Agonist Semaglutide Completes Phase III Trial with Positive Results
Posted August 07, 2015
Ketoacidosis Not as Great as Thought in Diabetes Patients Taking Invokana
Posted August 13, 2015
Impact of Switching Insulin Glargine to Insulin Detemir in T2 Patients
Posted August 14, 2015
SIgnificant Weight Gain Associated with Laparoscopic Sleeve Gastrectomy
Posted August 14, 2015
Two New Possible Methods for Diagnosing and Monitoring Diabetes
Posted August 07, 2015
Diabetes Combination Drug LixiLan Meets Main Target in Late Stage Trial
Posted August 07, 2015
Soybean Oil Causes More Obesity and Diabetes Than Fructose
Posted August 20, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
What percentage of your patients have reached goal for A1c, BP and cholesterol?

CME/CE of the Week
William Tamborlane, MD, FAAP, FACE

Category: General Diabetes
Credits:
 .75